WaveMan
WaveMan · Company
RDGL · Vivos Inc
> Search tickers & screens ⌘K
LIVE
← All companies

RDGL Vivos (RDGL) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001449349
Quote by TradingView
C-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

What the filings say about RDGL

Insiders, 180 days
+$141.4K net bought
2 buyers

Vivos insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, VIVOS INC insiders bought a net $141.4K of stock across 31 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Korenko Michael K
CEO
BUY
2026-10-01 SECtraded 2026-09-30
200,000
$99.6K
-4.4%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (22 buys, 1 sale), the last on Aug 10, 2026.
  • +5.8% median (+6.7% mean) 90-day return after 21 previous buys.
  • The trade is 1.7% of the 11,635,090 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: CEO Korenko Michael K bought about $99.6K of RDGL on Sep 30, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
Weeks Brad Allan
President
BUY
2026-09-16 SEC
25,550
$1.2K
-9.9%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Aug 10, 2026.
  • -32.1% median (-30.2% mean) 90-day return after 4 previous buys.
  • The trade is 1.7% of the 1,547,204 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: President Weeks Brad Allan bought about $1.2K of RDGL on Sep 16, 2026; 1 other insider bought within 30 days.
Korenko Michael K
CEO AND PRESIDENT
BUY
2026-08-10 SEC
150,000
$8.0K
-16.4%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (21 buys, 1 sale), the last on Jul 15, 2026.
  • +5.8% median (+6.7% mean) 90-day return after 21 previous buys.
  • The trade is 1.3% of the 11,435,090 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: CEO AND PRESIDENT Korenko Michael K bought about $8.0K of RDGL on Aug 10, 2026; 1 other insider bought within 30 days.
Weeks Brad Allan
President
BUY
2026-08-10 SEC
50,000
$2.7K
-16.4%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Jul 22, 2026.
  • -32.1% median (-30.2% mean) 90-day return after 4 previous buys.
  • The trade is 3.3% of the 1,521,654 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: President Weeks Brad Allan bought about $2.7K of RDGL on Aug 10, 2026; 1 other insider bought within 30 days.
Weeks Brad Allan
President
BUY
2026-07-22 SEC
32,000
$1.6K
-25.4%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 21, 2026.
  • -44.0% median (-33.5% mean) 90-day return after 3 previous buys.
  • The trade is 2.2% of the 1,471,654 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: President Weeks Brad Allan bought about $1.6K of RDGL on Jul 22, 2026; 1 other insider bought within 30 days.
31 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 26 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$141.4K over 180 days
+$111.5K over 90 days
more than 75% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+144.3% year over year
more than 95% of Medical Devices
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
the lowest in Medical Devices
What changed in the last 30 days
Oct 1CEO Korenko Michael K bought $99.6K (Sep 30)

Watch RDGL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-45.2%12M
-46%-25%-5%+16%2025-102025-122026-022026-042026-062026-082026-10 2026-09-30 · Korenko Michael K bought $99.6K2025-12-31 · Korenko Michael K bought $12.0K2026-07-15 · Korenko Michael K bought $11.4K2026-05-11 · Korenko Michael K bought $9.0K2026-08-10 · Korenko Michael K bought $8.0K2025-12-02 · Korenko Michael K bought $7.0K2025-11-20 · Korenko Michael K bought $6.0K2026-07-09 · Weeks Brad Allan bought $3.8K2026-07-21 · Weeks Brad Allan bought $3.0K2026-08-10 · Weeks Brad Allan bought $2.7K2026-07-22 · Weeks Brad Allan bought $1.6K2026-09-16 · Weeks Brad Allan bought $1.2K2026-07-10 · Weeks Brad Allan bought $960
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RDGL: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in RDGL

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RDGL planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $141.4K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

RDGL financials

Revenue growth
+144.3%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$99.1K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-132.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-127.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-102.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$68.4K$28.0K$19.5K$36.5K
Gross profit-$59.8K-$3.0K-$6.0K$7.7K
Operating income-$3.2M-$2.6M-$2.8M-$2.5M
Net income-$3.1M-$2.9M-$2.9M-$2.5M
EPS (diluted)-0.01-0.01-0.01-0.01
Operating cash flow-$2.1M-$1.7M-$1.3M-$1.1M
Cashn/a$2.2M$1.6M$1.7M
SEC XBRL, fiscal years, as known on 2026-10-28

RDGL Stock Sonar score 4/7 axes

Find similar shapesCompare

RDGL ranks highest on growth (95th percentile) and risk and compliance (81st), and lowest on profitability (17th), among Medical Devices peers.

Profitability
17
Inputs
  • Return on equity-132.5% · 22 pct, sector of 183
  • Return on assets-127.3% · 13 pct, sector of 214
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-102.6% · 17 pct, sector of 188
Growth
95
Inputs
  • Revenue growth, YoY+144.3% · 95 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
74
Inputs
  • Net Form 4 buying (codes P and S), 180d$141K · 75 pct, sector of 140
  • Insider buyers, 180d2 · 74 pct, sector of 142
Risk and compliance
81
Inputs
  • Short interest, % of float+0.0% · 100 pct, sector of 241
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+8.2% · 62 pct, sector of 198
3 not measured: Financial health, Institutional and government, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

RDGL filings, in plain words

Are Vivos insiders buying or selling RDGL?

In the 180 days to 2026-10-28, Vivos insiders were net buyers, a net $141.4K across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, Vivos insiders were net buyers of RDGL, a net $141.4K across purchases and sales reported on Form 4 by 2 buyers. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies